Qualigen Therapeutics (NASDAQ:AIXC) Issues Earnings Results

Qualigen Therapeutics (NASDAQ:AIXC) issued its earnings results on Friday. The company reported ($0.21) EPS for the quarter, FiscalAI reports.

Here are the key takeaways from Qualigen Therapeutics’ conference call:

• RoboShare is now AIXC’s top priority for the second half of 2026, with a Los Angeles pilot targeted to begin marketplace-facilitated rental activity in August. Management expects the pilot to provide a potential path to initial third-quarter revenue, subject to operational readiness and revenue-recognition requirements.
• Operating expenses fell to $2.96 million in Q2 from $4.33 million in Q1, helped by lower marketing, legal, and accounting costs. The company also reported no new share issuance during the quarter, and current liabilities declined substantially from year-end.
• Liquidity remains constrained: AIXC ended June with only $577,000 in cash, while its additional $5.2 million of digital assets are volatile and not cash equivalents. Operating cash use was approximately $3.4 million in Q2, and the company’s filings continue to disclose substantial doubt about its ability to continue as a going concern.
• The company reported a $4.19 million Q2 net loss, compared with $1.69 million a year earlier, including a $984,000 unrealized loss on digital assets. EAI Platform and RWA tokenization initiatives have been pushed to longer timelines, with previously indicated dates no longer reliable.
• Management is developing a “Robot Second Life Cycle” that would use rental data, service history, and utilization metrics to support future robot resale and valuation markets. Expansion beyond Los Angeles, including Silicon Valley and New York, will depend on pilot performance, partner readiness, economics, and available capital.

Qualigen Therapeutics Stock Down 0.4%

AIXC opened at $0.82 on Friday. The company has a market cap of $16.64 million, a PE ratio of -0.13 and a beta of 0.53. Qualigen Therapeutics has a 12 month low of $0.62 and a 12 month high of $8.81. The company has a fifty day moving average of $1.06.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Qualigen Therapeutics in a research note on Tuesday, July 21st. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Qualigen Therapeutics has a consensus rating of “Sell”.

Qualigen Therapeutics Company Profile

Qualigen Therapeutics, Inc, a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient’s blood.